Abstract：Objective To analyze the hepatitis B virus serological markers (HBVM) and abnormal rates of liver function indexes among primary liver cancer (PLC) patients with different HBVM profiles, so as to provide a reference for risk stratification and optimization of diagnosis and treatment strategies for PLC patients. Methods Patients diagnosed with PLC at Qidong People's Hospital between January 2017 and June 2024 were selected for this study. Basic information such as gender and age was collected through the hospital information management system. Venous blood samples were drawn to test for HBsAg, anti-HBs, HBeAg, anti-HBe, and anti-HBc, as well as ten liver function indexes such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), cholinesterase (CHE), and adenosine deaminase (ADA). Compare the abnormal rates of liver function indexes among the six HBVM profiles: "big three yang" (HBsAg+, HBeAg+, anti-HBc+), "small three yang" (HBsAg+, anti-HBe+, anti-HBc+), triple antibody positive (anti-HBs+, anti-HBe+, anti-HBc+), s/c antibody positive (anti-HBs+, anti-HBc+), e/c antibody positive (anti-HBe+, anti-HBc+), and all negative. Results A total of 1 434 patients with PLC were enrolled in this study. Among them, 1 043 (72.73%) were males and 391 (27.27%) were females. The median age was 64.00 (interquartile range, 16.00) years. The positive rates for HBsAg, anti-HBs, HBeAg, anti-HBe, and anti-HBc were 51.95%, 29.43%, 10.81%, 60.32%, and 88.42%, respectively. The "big three yang", "small three yang", triple-antibody positive, s/c antibody positive, e/c antibody positive, and all-negative profiles accounted for 85 (5.93%), 491 (34.24%), 170 (11.85%), 148 (10.32%), 100 (6.97%), and 121 (8.44%) cases, respectively. The abnormal rates of ALT among PLC patients with six HBVM profiles were 26.19%, 28.33%, 13.94%, 22.60%, 20.41%, and 14.91%, respectively. The abnormal rates of AST were 33.33%, 36.17%, 23.03%, 24.66%, 22.45%, and 18.42%, respectively. The abnormal rates of LDH were 62.16%, 68.22%, 53.73%, 61.19%, 60.00%, and 68.42%, respectively. The abnormal rates of CHE were 0%, 1.81%, 0%, 2.11%, 2.22%, and 3.88%, respectively. The abnormal rates of ADA were 59.09%, 57.27%, 24.27%, 33.33%, 45.00%, and 37.04%, respectively. These differences were statistically significant (all P<0.05). Conclusions In this study, the HBVM profiles were mainly characterized by "small triple positive" among PLC patients. The significant differences in liver function indexes abnormal rates among PLC patients with six HBVM profiles could reflect the liver injury status.
彭丽君, 龚莉, 季沈杰, 薛学锋, 陈建国. 原发性肝癌患者乙型肝炎病毒血清标志物和肝功能指标分析[J]. 预防医学, 2025, 37(10): 1024-1028.
PENG Lijun, GONG Li, JI Shenjie, XUE Xuefeng, CHEN Jianguo. Hepatitis B virus serological marker and liver function index among patients with primary liver cancer. Preventive Medicine, 2025, 37(10): 1024-1028.
[1] TAN E Y,DANPANICHKUL P,YONG J N,et al.Liver cancer in 2021:global burden of disease study[J].J Hepatol,2025,82(5):851-860. [2] 郑荣寿,陈茹,韩冰峰,等.2022年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志,2024,46(3):221-231. ZHENG R S,CHEN R,HAN B F,et al.Cancer incidence and mortality in China,2022[J].Chin J Oncol,2024,46(3):221-231.(in Chinese) [3] 焦娇,郭意男,章国君,等.乙肝肝硬化进展原发性肝癌的危险因素研究[J].预防医学,2019,31(4):363-366,370. JIAO J,GUO Y N,ZHANG G J,et al.Advance in research of risk factors for hepatitis B cirrhosis progressing to primary hepatic carcinoma[J].China Prev Med J,2019,31(4):363-366,370.(in Chinese) [4] NASSER N,TONNERRE P,MANSOURI A,et al.Hepatitis-B virus:replication cycle,targets,and antiviral approaches[J/OL].Curr Opin Virol,2023,63[2025-09-02].https://doi.org/10.1016/j.coviro.2023.101360. [5] KAO J H.Role of viral factors in the natural course and therapy of chronic hepatitis B[J].Hepatol Int,2007,1(4):415-430. [6] 陆建华,黄飞,倪正平,等.肝癌高发区各种人群中HBV五项标志的常见模式[J].医学理论与实践,1991,4(4):1-4. LU J H,HUANG F,NI Z P,et al.Common patterns of five HBV markers in various populations in high incidence areas of liver cancer[J].J Med Theory Pract,1991,4(4):1-4.(in Chinese) [7] World Health Organization.Guidelines for the prevention,diagnosis,care and treatment for people with chronic hepatitis B infection(text extract):executive summary[J].Infect Dis Immun,2024,4(3):103-105. [8] ODENWALD M A,PAUL S.Viral hepatitis:past,present,and future[J].World J Gastroenterol,2022,28(14):1405-1429. [9] CHEN J G,KENSLER T W,ZHU J,et al.Profound primary prevention of liver cancer following a natural experiment in China:a 50-year perspective and public health implications[J].Int J Cancer,2025,156(4):756-763. [10] 任宏武. 乙肝两对半不同模式与原发性肝癌关系的探讨[J].中国社区医师,2018,34(17):128-129. REN H W.Study on the relationship between different modes of five items of hepatitis B with liver cancer[J].Chin Community Dr,2018,34(17):128-129.(in Chinese) [11] European Association for the Study of the Liver.EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J].J Hepatol,2017,67(2):370-398. [12] TERRAULT N A,BZOWEJ N H,CHANG K M,et al.AASLD guidelines for treatment of chronic hepatitis B[J].Hepatology,2016,63(1):261-283. [13] 王馨,唐小琼,韩宁,等.乙型肝炎病毒生物标志物的研究进展及其临床意义[J].生物医学工程学杂志,2023,40(6):1242-1248. WANG X,TANG X Q,HAN N,et al.Research progress of biomarkers of hepatitis B virus and clinical significance[J].J Biomed Eng,2023,40(6):1242-1248.(in Chinese) [14] TIWARI-HECKLER S,YEE E U,YALCIN Y,et al.Adenosine deaminase 2 produced by infiltrative monocytes promotes liver fibrosis in nonalcoholic fatty liver disease[J].Cell Rep,2021,37(4):1-20.
